Rad6在肺腺癌中的表达及临床意义

Expression of Rad6 in lung adenocarcinoma and its clinical significance

目的:研究Rad6在肺腺癌组织中的表达情况,探讨其与肺腺癌预后的相关性。方法:选择92例有完整随访资料的肺腺癌患者的新鲜癌组织及相应的癌旁正常肺组织标本(距肿瘤边缘>5 cm),应用免疫组织化学EnVision两步法,分别检测癌组织及癌旁正常肺组织中Rad6蛋白的表达水平。结果:肺腺癌组织中Rad6的蛋白表达水平明显高于癌旁正常肺组织(61.96%vs 38.04%,P<0.05)。其蛋白高表达与肿瘤的病理分期、分化程度和淋巴结转移相关(P<0.05),且肺腺癌患者中Rad6高表达者总生存率明显下降(P<0.05)。结论:Rad6在肺腺癌组织中的表达水平高于相应癌旁正常肺组织,且肿瘤分化程度越低,Rad6蛋白的表达水平越高,生存时间越短,提示Rad6过表达与肺腺癌的发生发展及预后有关。

Objective:To investigate the expression of Rad6 in lung adenocarcinoma and analyze the clinical significance.Methods:Carcinoma and corresponding para-carcinoma(more than 5 cm from the edge of the tumor)tissue specimens were collected from 92 lung adenocarcinoma patients with complete follow-up data.Immunohistochemical method was used to detect the expression of Rad6 in lung adenocarcinoma tissues and sectional para-carcinoma tissues.Results:The expression of Rad6 was higher in lung adenocarcinoma than that in para-carcinoma tissues(61.96%vs 38.04%,P<0.05).Rad6 expression was associated with the pathological stage,differentiation degree,and lymphnode metastasis of tumors.Conclusion:The expression of Rad6 is higher in lung adenocarcinoma with low-differentiated,and it has lower overall survival,suggesting that Rad6 overexpression is related to the occurrence,development and prognosis of lung adenocarcinoma.